Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04153396 |
Recruitment Status :
Completed
First Posted : November 6, 2019
Last Update Posted : March 14, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Postoperative Neurosurgery | Drug: The Treatment group Drug: The Control group | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 116 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE) |
Actual Study Start Date : | September 1, 2021 |
Actual Primary Completion Date : | December 3, 2021 |
Actual Study Completion Date : | June 3, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: The Treatment Group
The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
|
Drug: The Treatment group
The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated. |
Active Comparator: The Control group
The local infiltration solution in the control group will consist of ropivacaine.
|
Drug: The Control group
The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated. |
- The cumulative butorphanol dose during the 48 hours after surgery via the PCA device. [ Time Frame: Within 48 hours after the operation ]All participates will receive an electronic intravenous patient-controlled analgesia (PCA) device. Participates will be advised to push the analgesic demand button if they feel pain.
- The Visual Analogue Scale (VAS) during movement (VASm) [ Time Frame: At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours, and 1 week, 2 weeks, 4 weeks, 6 weeks and 3 months and 6 months after surgery. ]The pain will be assessed by the visual analogue scale (VAS) scores: an 11-point VAS score during movement (VASm) will be recorded (0 indicates no pain, 10 indicates the most severe pain imaginable, a higher score means worse pain)
- The Visual Analogue Scale (VAS) at rest (VASr) [ Time Frame: At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours and 72 hours, and 1 week, 2 weeks, 4 weeks, 6 weeks and 3 months and 6 months after surgery. ]The pain will be assessed by the visual analogue scale (VAS) scores: an 11-point VAS score at rest (VASr) will be recorded (0 indicates no pain, 10 indicates the most severe pain imaginable, a higher score means worse pain)
- The total times that participants press patient-controlled analgesia button [ Time Frame: Within 48 hours after the operation ]The total times that participants press patient-controlled analgesia button including effective presses and ineffective presses.
- The first analgesia demand on the PCA device [ Time Frame: Within 48 hours postoperatively ]The time from the end of the surgery to the first administration of analgesia via the PCA device
- Patient Satisfaction Score (PSS) [ Time Frame: At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 4 weeks, 6 weeks, 3 months and 6 months after surgery ]The Patient Satisfaction Score (PSS): 0 for unsatisfactory, and 10 for very satisfied
- The Postoperative Nausea and Vomiting (PONV) [ Time Frame: At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours after surgery ]The Postoperative Nausea and Vomiting (PONV) will be measured using an ordinal scale, with 0 indicating no nausea; 1, mild nausea not requiring treatment; 2, nausea requiring treatment; 3, vomiting.
- Ramsay Sedation Scale (RSS) [ Time Frame: At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours after surgery ]The Ramsay Sedation Scale (RSS): A 6-point scale will be used to assess sedation levels, with 1 indicating agitated, anxious; 2, cooperative; 3, only responds to commands; 4, strong response to glabellar tapping or noisy stimulants; 5, weak response to glabellar tapping or noisy stimulants; 6, no response.
- The World Health Organization Quality of Life-BREF (WHOQOL-BREF) scores [ Time Frame: At 6 months postoperatively ]The World Health Organization Quality of Life-BREF (WHOQOL-BREF) scores will be used to obtain scores for four domains related to quality of life: physical health (7 items), psychological (6 items), social relationships (3items) and environment (8items). It will also include two stand-alone questions on overall quality of life and satisfaction with health. Each question will be rated on a scale of 1-5 with higher scores signifying better quality of life.
- The Oswestry Disability Index (ODI) [ Time Frame: Preoperatively and at 4 weeks, 6 weeks and 3 months, 6 months after surgery. ]Functional disability will be assessed by the Oswestry Disability Index. It includes 10 questions about pain and activities of daily living. Each item has five response categories from no pain related disability (0), to the worst possible pain disability (100). The ODI has been reported to be the most widely used and validated outcome measure in spinal surgery.
- Patient Scar Assessment and the Observer Scar Assessment Scale (POSAS) [ Time Frame: At 6 months postoperatively ]The Patient and Observer Scar Assessment Scale includes subjective symptoms of pain and pruritus and consists of 2 numerical scales: The Patient Scar Assessment Scale and the Observer Scar Assessment Scale. It assesses vascularity, pigmentation, thickness, relief, pliability, surface area and overall opinion for a scar on a score of 1 (normal skin) to 10 (worst scar imaginable). and it incorporates patient assessments of pain, itching, color, stiffness, thickness, relief and overall opinion. Participants were asked to rate the severity of their scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (very different from normal skin)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled for surgery under general anaesthesia for laminectomy or laminoplasty;
- American Society of Anaesthesiologists (ASA) classification of I or II;
- Age 18 to 64 years;
- Participates with an anticipated full recovery within 2 hours postoperatively.
Exclusion Criteria:
- Patient refusal;
- Participants who cannot use a patient-controlled analgesia (PCA) device and cannot understand the instructions of a Visual Analogue Score (VAS);
- Previous history of spinal surgery;
- Allergy to opioids, betamethasone or ropivacaine;
- Peri-incisional infection;
- History of stroke or a major neurological deficit;
- Trauma, deformity;
- Psychological problems;
- Extreme body mass index (BMI) (< 15 or > 35);
- History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects;
- Patients using systemic steroids;
- Pregnant or breastfeeding;
- Preoperative Glasgow Coma Scale < 15;
- Participants who have received radiation therapy or chemotherapy preoperatively, or with a high probability to require a postoperative radiation therapy or chemotherapy according to the preoperative imaging.
- Not able to give written informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04153396
China, Beijing | |
Beijing Tiantan Hospital | |
Beijing, Beijing, China, 100070 |
Principal Investigator: | Fang Luo, M.D. | Beijing Tiantan Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Fang Luo, Director of Department of Pain Management, Beijing Tiantan Hospital |
ClinicalTrials.gov Identifier: | NCT04153396 |
Other Study ID Numbers: |
KY 2019-112-02-1 |
First Posted: | November 6, 2019 Key Record Dates |
Last Update Posted: | March 14, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Pain, Postoperative Betamethasone; Ropivacaine; Wound Infiltration Laminoplasty or Laminectomy |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations |